CCL2 and serum lipopolysaccharide activity: In a human experimental endotoxemia model conducted by Thomas et al. [48], clopidogrel and ticagrelor were able to reduce peak levels of D-dimer and major proinflammatory cytokines, including interleukin-6, tumor necrosis factor-α and monocyte chemoattractant protein-1.